GlassScriptPhysician profile
Edward H Booker
NPI 1386701563
$7,146.28
in general payments reported to CMS, 2019-2025
45 companies · $951 in 2025
The $951 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $785 · 2021: $1,594 · 2022: $1,285 · 2023: $1,034 · 2024: $828 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,813.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,121.56 | 2020-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $572.84 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $563.24 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $471.93 | 2019-2025 | Otezla, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $456.61 | 2019-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $374.31 | 2019-2025 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.21 | 2021-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $267.40 | 2019-2024 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $227.84 | 2019-2021 | |
| Abbott Laboratories | $213.78 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Pfizer INC. | $207.43 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $191.08 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $172.48 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $156.27 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $139.18 | 2019-2023 | Xarelto |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $124.00 | 2021-2022 | |
| Antares Pharma, INC. | $109.73 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Mylan Specialty L.P. | $105.91 | 2020-2021 | |
| Daiichi Sankyo INC. | $101.72 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.17 | 2021-2024 | |
| Axsome Therapeutics, INC. | $91.25 | 2024-2025 | Auvelity |
| Eisai INC. | $86.74 | 2020-2023 | |
| Astellas Pharma US INC | $80.15 | 2019-2020 | |
| Dexcom, INC. | $76.89 | 2022-2024 | Dexcom G6 Transmitter |
| Tris Pharma INC | $76.72 | 2023-2024 | Dyanavel Xr |
| Lundbeck LLC | $76.48 | 2022-2023 | Rexulti |
| Allergan, INC. | $72.34 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.96 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.63 | 2019-2021 | |
| Insulet Corporation | $52.66 | 2025 | Omnipod |
| Idorsia Pharmaceuticals US INC | $48.92 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $45.93 | 2023 | Cologuard Collection Kit |
| Corcept Therapeutics | $45.36 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $43.18 | 2020-2022 | |
| Adlon Therapeutics L.P. | $41.32 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $34.41 | 2025 | Fanapt, Hetlioz |
| Arbor Pharmaceuticals, INC. | $28.80 | 2020 | |
| Insmed, INC. | $28.42 | 2021 | |
| Tandem Diabetes Care, INC. | $27.24 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Forte Bio-Pharma LLC | $22.19 | 2021 | |
| Shire North American Group INC | $21.26 | 2019 | |
| Genentech USA, INC. | $20.92 | 2019 | |
| Esperion Therapeutics, INC. | $16.50 | 2021 | |
| Aimmune Therapeutics, INC. | $13.90 | 2025 | Zenpep |
| Currax Pharmaceuticals LLC | $13.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Booker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.